Continuous Subcutaneous Foslevodopa/Foscarbidopa After Deep Brain Stimulation or Levodopa–Carbidopa Intestinal Gel: A Case Series in Advanced Parkinson’s Disease
Objective: To describe indications and short-term outcomes of FLC/FCD in PD patients previously treated with DBS and/or LCIG. Background: Advanced Parkinson's disease patients treated with…Inpatient Titration Protocol and Practical Implementation of Continuous Subcutaneous Foslevodopa/Foscarbidopa: Lessons from 28 Consecutive Cases
Objective: To describe inpatient titration methodology, dosing parameters, support services utilization, and early challenges in consecutive advanced PD patients. Background: Successful implementation of continuous subcutaneous…Associations Between Saccadic and Motoric Symptoms in Parkinson’s Disease
Objective: To explore associations between saccadic measures and i) global motor, ii) non-tremor motor, and iii) tremor severity in Parkinson’s disease (PD). Background: Impaired voluntary…Beyond Motor Fluctuations: Non-Motor and Quality-Of-Life Outcomes with Subcutaneous Foslevodopa/Foscarbidopa Infusion in Real-World Practice
Objective: To evaluate motor and non-motor outcomes, including sleep disturbances, of continuous subcutaneous foslevodopa/foscarbidopa infusion in a heterogeneous real-world cohort of patients with advanced Parkinson’s…Evaluating the GBA1 Intronic rs3115534-G PD Risk Variant in the PD GENEration Cohort
Objective: To investigate the frequency of a newly proposed PD risk factor in an intronic region of GBA1 in people with PD from the PD…Digital Respiratory Biomarkers as Early Indicators of Dysphagia and Aspiration Risk in Parkinsons Disease A Systematic Review
Objective: To evaluate evidence linking respiratory dysfunction with dysphagia and aspiration risk in Parkinson’s disease (PD) and examine the potential role of digital respiratory biomarkers…Genome-wide Discovery of GBA1 Modifiers in Parkinsons Disease Carriers across Populations from the Global Parkinsons Genetics Program
Objective: To identify genetic risk modifiers for GBA1 risk variant carriers of European and African ancestry, we used data from GP2 (http://gp2.org/), the UK Biobank,…Developing a Unified Advanced Neuromodulation Clinical Pathway for MR-Guided Focused Ultrasound and Deep Brain Stimulation
Objective: To analyze determinants of neuromodulation treatment selection, including patient preferences and clinical eligibility, in a large real-word cohort of patients diagnosed with Parkinson’s Disease (PD) and Essential…Identifying Peripheral Stimulation Sites to Treat Parkinson’s Disease Gait Impairments
Objective: Our aim is to develop a non-invasive treatment for Parkinson’s Disease gait symptoms by applying peripheral stimulation to the feet using coordinated reset stimulation…Resting-state network reorganization following multimodal lifestyle intervention in Parkinson’s disease
Objective: To investigate longitudinal changes in resting-state (rs) functional connectivity following a multimodal lifestyle intervention in individuals with Parkinson's disease (PD). Background: PD is associated with disruption of large-scale…
- « Previous Page
- 1
- …
- 138
- 139
- 140
- 141
- 142
- …
- 208
- Next Page »